-
11.发明公开公开(公告)号：US20240262932A1
公开(公告)日：2024-08-08
申请号：US18640824
申请日：2024-04-19
Applicant: Genentech, Inc.
Inventor： Reed J. HARRIS , Paul A. MOTCHNIK
CPC classification number: C07K16/32 , C07K1/18 , C07K16/065 , C07K16/2863 , C07K16/2896 , A61K2039/505 , C07K2317/24 , C07K2317/41 , C07K2317/76 , G01N27/447 , G01N30/02 , G01N2030/027
Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
-
公开(公告)号：US12054751B2
公开(公告)日：2024-08-06
申请号：US18066303
申请日：2022-12-15
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Gang Chen , Darya Burakov , James P. Fandl
CPC classification number: C12N9/0006 , C12N15/00 , C12P21/005 , C12Y101/01271 , C07K16/00 , C07K16/2863 , C07K16/2866 , C07K2317/14 , C07K2317/41 , Y02P20/52
Abstract: An isolated nucleic acid encoding an FX protein having a serine at position 79, a lysine at position 90, a leucine at position 136, an arginine at position 211, a serine at position 289, and a combination thereof is provided. Cells having a gene encoding a modified FX protein are provided, wherein the cells exhibit a reduced ability to fucosylate a glycoprotein at a first temperature, but exhibit the ability to fucosylate the glycoprotein at a second temperature. Methods and compositions for making glycoproteins with reduced fucosylation are provided.
-
13.发明公开
公开(公告)号：US20240254214A1
公开(公告)日：2024-08-01
申请号：US18360073
申请日：2023-07-27
Applicant: REGENXBIO Inc. , The Johns Hopkins University
Inventor： Stephen Yoo , Rickey Robert Reinhardt , Sherri Van Everen , Karen Fran Kozarsky , Curran Matthew Simpson , Zhuchun Wu , Peter Anthony Campochiaro , Jikui Shen , Kun Ding
IPC: C07K16/22 , A61F9/00 , A61K9/00 , A61M25/00 , A61M25/01 , A61P27/02 , C12N7/00 , C12N15/86 , A61K39/00 , A61K48/00
CPC classification number: C07K16/22 , A61F9/0017 , A61K9/0019 , A61K9/0048 , A61M25/0084 , A61M25/0194 , A61P27/02 , C12N7/00 , C12N15/86 , A61K2039/505 , A61K48/00 , A61M2025/0089 , A61M2210/0612 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C12N2750/14143 , C12N2750/14171
Abstract: Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”) —such as, e.g., a fully human-glycosylated (HuGly) anti-h VEGF antigen-binding fragment—to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.
-
公开(公告)号：US20240209117A1
公开(公告)日：2024-06-27
申请号：US18507869
申请日：2023-11-13
Applicant: GENMAB A/S
Inventor： Aran Frank LABRIJN , Joyce I. MEESTERS , Edwald T. J. VAN DER BREMER , Joost J. NEIJSSEN , Patrick VAN BERKEL , Bart DE GOEIJ , Tom VINK , Jan VAN DE WINKEL , Janine SCHUURMAN , Paul PARREN
CPC classification number: C07K16/468 , C07K16/1063 , C07K16/2809 , C07K16/2863 , C07K16/2887 , C07K16/32 , C07K16/40 , G01N33/6854 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/41 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins
-
公开(公告)号：US20240182588A1
公开(公告)日：2024-06-06
申请号：US18512759
申请日：2023-11-17
Applicant: Vaccinex, Inc.
Inventor： Pamela M. HOLLAND , Andrew LAKE , Austin DULAK , Ernest Smith , Maria Scrivens , Caroline Harvey , Renee Kirk , Leslie Balch , Sonia DAS , Christopher Converse Wells
CPC classification number: C07K16/2866 , A61K47/6803 , A61K47/6849 , A61P35/00 , C07K2317/31 , C07K2317/41 , C07K2317/622 , C07K2317/732 , C07K2317/92
Abstract: The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
-
公开(公告)号：US20240167069A1
公开(公告)日：2024-05-23
申请号：US18218996
申请日：2023-07-06
Applicant: Momenta Pharmaceuticals, Inc.
Inventor： Naveen Bhatnagar , Robin Meccariello , Jonathan C. Lansing , Daniel Ortiz , Hetal Sarvaiya , Nathaniel J. Washburn
CPC classification number: C12P21/005 , C07K16/00 , C12N9/1081 , C12Q1/48 , C12Y204/99001 , C12Y204/99003 , C07K2317/41 , C07K2317/52 , G01N2333/91091 , G01N2440/38
Abstract: Glycoproteins having particular sialylation patterns, and methods of making and using such glycoproteins, are described.
-
公开(公告)号：US11976131B2
公开(公告)日：2024-05-07
申请号：US17264209
申请日：2019-07-30
Applicant: Heidelberg Pharma Research GmbH
Inventor： Torsten Hechler , Andreas Pahl
CPC classification number: C07K16/3069 , A61P35/00 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/622 , C07K2317/92
Abstract: The present application relates to humanized and/or deimmunized antibodies, antibody fragments or antibody derivatives that bind to Prostate Specific Membrane Antigen (PSMA) and methods for using said antibodies, antibody fragments or antibody derivatives in the treatment of prostate cancer and other neoplastic as well as neurological diseases.
-
公开(公告)号：US20240141021A1
公开(公告)日：2024-05-02
申请号：US18253386
申请日：2021-11-19
Applicant: Vir Biotechnology, Inc. , Humabs BioMed SA
Inventor： Davide CORTI , Matteo Samuele PIZZUTO , Andrea MINOLA , Elisabetta CAMERONI , Fabrizia ZATTA , Gyorgy SNELL , Elena FERRI
CPC classification number: C07K16/1018 , A61P31/16 , A61K2039/507 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/72 , C07K2317/76
Abstract: The present disclosure relates, in part, to anti-influenza antibodies (and antigen binding fragments thereof) and combinations thereof for preventing and treating influenza infection. Presently disclosed combinations provide surprising synergistic effects and can potently prevent, inhibit, or neutralize an influenza infection, such as an influenza A virus (IAV) infection an influenza B virus (IBV) infection, or both.
-
公开(公告)号：US11970541B2
公开(公告)日：2024-04-30
申请号：US17531011
申请日：2021-11-19
Applicant: BEIJING MABWORKS BIOTECH CO. LTD.
Inventor： Feng Li , Boyan Zhang , Pei Ye
CPC classification number: C07K16/2887 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/02 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C07K2317/734 , C07K2317/90 , C07K2317/94
Abstract: The present invention relates to a humanized anti-CD20 antibody that comprises an antigen binding site containing heavy and light chain of obinutuzumab (GAZYVA®), and N-linked oligosaccharides that are attached to the Fc region of the antibody, wherein the N-linked oligosaccharides are not bisected by N-acetylglucosamine. The antibody of the present invention comprises fucose glycotype in an amount of no more than 10% of the total N-glycans that are attached to the Fc region of the antibody. The anti-CD20 of the present invention has antibody dependent cell-mediated cytotoxicity (ADCC) about 2 times stronger than that of GAZYVA® and about 50 to 100 times stronger than that of RITUXAN®. The anti-CD20 antibodies are effective for treating CD20 expressing cancer, such as non-Hodgkin's lymphoma, B cell lymphoma, chronic lymphocytic leukemia, or follicular lymphoma.
-
公开(公告)号：US11958901B2
公开(公告)日：2024-04-16
申请号：US17100245
申请日：2020-11-20
Applicant: PFIZER INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor： Rachel Groth , William Brian Snyder , Xianjun Cao , Robert Joseph Dunn , Joseph Dal Porto , Michael Karin
CPC classification number: C07K16/24 , A61P19/02 , A61P37/06 , C07K16/2866 , C07K16/40 , C12N15/62 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/41 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to CXCR5. The antibodies can be afucosylated and exhibit increased ADCC compared with the otherwise identical fucosylated antibodies. The invention includes uses, and associated methods of using the antibodies.
